Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4465
Name papillary renal cell carcinoma
Definition A renal cell carcinoma that is characterized by the development of multiple, bilateral papillary renal tumors.
Source DiseaseOntology.org
Alt Ids DOID:8063
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma papillary renal cell carcinoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
EML4 - ALK Alectinib papillary renal cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00831480 Phase II Everolimus Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal Terminated USA 0
NCT01130519 Phase II Bevacizumab + Erlotinib A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer Active, not recruiting USA 0
NCT02019693 Phase II Capmatinib A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer Completed USA 0
NCT02127710 Phase II Savolitinib A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) Completed USA | ESP | CAN 1
NCT02761057 Phase II Savolitinib Cabozantinib Crizotinib Sunitinib Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Active, not recruiting USA | CAN 0
NCT02837991 Phase Ib/II CDX-014 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma Terminated USA 0
NCT02915783 Phase II Everolimus + Lenvatinib A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease Completed USA 0
NCT03091192 Phase III Sunitinib Savolitinib Savolitinib vs. Sunitinib in MET-driven PRCC. Active, not recruiting USA | ITA | FRA 4
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting USA | ITA | FRA | ESP | CAN | BEL | AUT 12
NCT03541902 Phase II Cabozantinib Sunitinib Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma Active, not recruiting USA 0
NCT03685448 Phase II Cabozantinib ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB) Recruiting 1
NCT03866382 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting USA 1
NCT04071223 Phase II Cabozantinib + Radium Ra 223 dichloride Cabozantinib Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study Recruiting USA 0
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting USA 5
NCT04267120 Phase II Lenvatinib + Pembrolizumab Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) Recruiting USA 0
NCT04338269 Phase III Cabozantinib Atezolizumab + Cabozantinib A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT04413123 Phase II Cabozantinib + Ipilimumab + Nivolumab Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Recruiting USA 0
NCT04834778 Phase I HC-5404-FU A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) Recruiting USA 0
NCT04981509 Phase II Atezolizumab + Bevacizumab + Erlotinib Testing of Bevacizumab, Erlotinib, and Atezolizumab for Advanced-Stage Kidney Cancer Suspended USA 0
NCT04991740 Phase I JNJ-78306358 A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors Recruiting ESP 1
NCT05043090 Phase III Durvalumab + Savolitinib Durvalumab Sunitinib Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA) Recruiting USA | ITA | FRA | ESP | DEU | CAN 19
NCT05096390 Phase II Axitinib + Pembrolizumab Axitinib Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC (PAXIPEM) Not yet recruiting FRA 0
NCT05176483 Phase I Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) Recruiting USA 0
NCT05323045 Phase I BYON3521 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 Recruiting ITA | BEL 2